Artiva Biotherapeutics, Inc. files with the SEC under CIK 0001817241 and is classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.84 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.82 to $9.97 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.96 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.16 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.72 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.40 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.79 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.88 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $8.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.62 to $8.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.97 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.31 to $8.64 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.96 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.63 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.77 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.605 to $8.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the… Full note on SEC EDGAR
Footnote F1 (shares): The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection… Full note on SEC EDGAR
Footnote F2 (price): The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7447 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each… Full note on SEC EDGAR
Footnote F1 (shares): The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection… Full note on SEC EDGAR
Footnote F2 (price): The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7421 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each… Full note on SEC EDGAR
Footnote F1 (shares): The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection… Full note on SEC EDGAR
Footnote F2 (price): The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7439 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each… Full note on SEC EDGAR
Footnote F1 (shares): The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection… Full note on SEC EDGAR
Footnote F2 (price): The weighted average sale price for the transaction reported was $9.0076, and the range of prices were between $8.7404 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each… Full note on SEC EDGAR
Footnote F1 (shares): The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection… Full note on SEC EDGAR
Footnote F2 (price): The weighted average sale price for the transaction reported was $9.0077, and the range of prices were between $8.7383 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each… Full note on SEC EDGAR
Footnote F1 (shares): Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
Footnote F2 (shares): Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
Footnote F1 (shares): Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
Footnote F2 (shares): Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
Footnote F1 (shares): Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
Footnote F2 (shares): Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
Footnote F1 (shares): Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
Footnote F2 (shares): Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
Footnote F1 (shares): Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
Footnote F2 (price): On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
Footnote F1 (shares): Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
Footnote F2 (price): On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
Footnote F1 (shares): Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
Footnote F2 (price): On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
Footnote F1 (shares): Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
Footnote F2 (price): On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
Footnote F1 (shares): Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
Footnote F1 (shares): Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
Artiva Biotherapeutics, Inc. (ARTV) had 35 insider filings in the last 90 days, with the most recent on 2026-10-07. The full record for ARTV runs to 71 Form 4 filings, the earliest from 2024-10-22. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ARTV stock?
8 insider purchases of ARTV were filed in the last 90 days, totaling $4.88M.
How many insiders are selling ARTV stock?
12 insider sales of ARTV were filed in the last 90 days, totaling $2.00M.
Where can I see ARTV SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ARTV Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.